Fracture risks associated with sodium-glucose cotransporter-2 inhibitors in type 2 diabetes patients across eGFR and albuminuria categories: A population-based study in Hong Kong
Authors' conclusion
Our study did not reveal a statistically significant increase in fracture risk with SGLT2i use compared with DPP4i among type 2 diabetes patients, across eGFR and albuminuria categories.
Study context
- Population
- T2D patients started on SGLT2i or DPP-4i during 2007–2020, Hong Kong Hospital Authority databasematched cohort
- Participants
- 28,696 patients
- Exposure
- SGLT2i vs DPP-4i
- SGLT2in = 14,348
- DPP4in = 14,348reference
- Outcome
- Risk of major osteoporotic fracture (MOF)
- Follow-up
- 180 and 365 days
Methodological detailsone-to-one propensity score matching
- One-to-one propensity score matching
Main finding
MOF · 180 days
Hazard ratio
1.13
95 % CI 0.65–1.98
P = 0.67
Events by group
Between SGLT2i and DPP4i
HR 1.13 (95 % CI 0.65–1.98); P = 0.67
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | SGLT2i | DPP4i | HR (95 % CI) | P value | |
|---|---|---|---|---|---|
| MOF (co-primary) · 365 days | 0.30 % | 0.31 % | 1.15 (0.75–1.75) | P = 0.52 | |
| Incidence | 4.16/1,000 person-years | 3.64/1,000 person-years | |||
| 0.512Hazard ratio (log scale) |
Subgroups by age, sex, eGFR, albuminuria, KDIGO category
- Subgroup analyses were consistent across age, sex, eGFR, albuminuria, or KDIGO categories
Original publication
Fracture risks associated with sodium-glucose cotransporter-2 inhibitors in type 2 diabetes patients across eGFR and albuminuria categories: A population-based study in Hong Kong. Diabetes Res Clin Pract. Published 11 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →